Want to see SE:XSPRAY full AI Analyst Report?
Xspray Pharma AB (XSPRAY) AI Stock Analysis
Xspray Pharma AB
(Nasdaq OMX AB:XSPRAY)
The score is primarily weighed down by weak financial performance (no revenue, ongoing losses, and persistent cash burn), partially offset by a relatively stronger balance sheet with moderate leverage. Technicals are mixed with a short-term rebound but a longer-term downtrend, and valuation remains constrained by negative earnings and no indicated dividend yield.
Xspray Pharma AB (XSPRAY) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 559.52M
- Dividend Yield
- ―
- Average Volume (3M)
- 116.23K
- Price to Earnings (P/E)
- -3.1
- Beta (1Y)
- 0.94
- Revenue Growth
- ―
- EPS Growth
- 44.46%
- Country
- Sweden
- Employees
- 24
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Xspray Pharma AB Business Overview & Revenue Model
Company Description
Xspray Pharma AB (publ), a pharmaceutical firm based in Solna, Sweden, specializes in developing protein kinase inhibitors for precise cancer treatments. Their current drug pipeline includes HyNap-Nilo, aimed at chronic myeloid leukemia; HyNap-Sora,...
How the Company Makes Money
Xspray Pharma’s business model is primarily based on monetizing its drug-formulation technology and product candidates rather than operating as a large-scale, fully integrated commercial drug company. The company can generate revenue through (1) lice...
Xspray Pharma AB Financial Statement Overview
Summary
Financials reflect an early-stage biotech profile: no revenue and persistent, material losses with negative operating and free cash flow. The balance sheet is comparatively stronger with substantial equity and moderate leverage, and losses/cash burn have improved versus prior years, but the company remains reliant on external funding.
Income Statement
18Very NegativeBalance Sheet
62PositiveCash Flow
27Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -2.78M | -5.58M | -8.55M | -9.19M | -9.53M | -8.87M |
| EBITDA | -132.72M | -156.27M | -274.69M | -169.81M | -122.13M | -87.82M |
| Net Income | -159.44M | -171.44M | -285.52M | -179.67M | -130.27M | -96.70M |
Balance Sheet | ||||||
| Total Assets | 811.18M | 769.35M | 796.34M | 765.26M | 585.43M | 622.90M |
| Cash, Cash Equivalents and Short-Term Investments | 179.91M | 153.75M | 208.24M | 166.30M | 120.17M | 271.88M |
| Total Debt | 147.30M | 170.11M | 128.22M | 36.81M | 2.13M | 3.23M |
| Total Liabilities | 173.68M | 164.70M | 173.25M | 71.85M | 29.41M | 31.15M |
| Stockholders Equity | 637.50M | 604.65M | 623.10M | 693.41M | 556.02M | 591.75M |
Cash Flow | ||||||
| Free Cash Flow | -161.72M | -222.35M | -264.51M | -257.38M | -238.47M | -147.57M |
| Operating Cash Flow | -150.34M | -193.16M | -222.37M | -203.28M | -110.18M | -51.61M |
| Investing Cash Flow | -19.73M | -29.19M | -42.14M | -65.88M | -135.34M | -105.82M |
| Financing Cash Flow | 276.11M | 168.29M | 306.11M | 315.59M | 93.81M | 103.71M |
Xspray Pharma AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XSPRAY, the sentiment is Positive. The current price of 11.80 is above the 20-day moving average (MA) of 10.73, above the 50-day MA of 10.26, and below the 200-day MA of 18.78, indicating a neutral trend. The MACD of 0.08 indicates Negative momentum. The RSI at 63.37 is Neutral, neither overbought nor oversold. The STOCH value of 63.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:XSPRAY.
Xspray Pharma AB Peers Comparison
Overall Rating
SE:CAMX80Outperform
SE:XBRANE53Neutral- SE:XSPRAY45Neutral
SE:SPAGO43Neutral
SE:VICO39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SE:CAMX | 80Outperform | SEK 40.76B | 59.09 | 15.54% | ― | <0.01% | -6.75% |
| SE:XBRANE | 53Neutral | SEK 291.57M | -5.90 | -13.41% | ― | -38.80% | -120.18% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SE:XSPRAY | 45Neutral | SEK 559.52M | -3.06 | -26.00% | ― | ― | 44.46% |
| SE:SPAGO | 43Neutral | SEK 32.09M | -0.85 | -106.23% | ― | -97.37% | 25.28% |
| SE:VICO | 39Underperform | SEK 2.73B | -5.05 | -53.71% | ― | -48.40% | -1.06% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:XSPRAY | Xspray Pharma AB | 11.80 | -12.80 | -52.04% | |
| SE:CAMX | Camurus AB | 673.00 | 46.00 | 7.34% | |
| SE:VICO | Vicore Pharma Holding AB | 9.70 | -1.18 | -10.85% | |
| SE:XBRANE | Xbrane Biopharma AB | 14.15 | 3.35 | 31.02% | |
| SE:SPAGO | Spago Nanomedical AB | 0.04 | -0.11 | -72.79% | |
| SE:BIOWKS | Bio-Works Technologies AB | 3.00 | 0.26 | 9.49% |
Xspray Pharma AB Corporate Events
Xspray Pharma Targets Q4 2026 FDA Resubmissions for Dasynoc and Nilopki
Xspray Pharma has reiterated plans to resubmit New Drug Applications for its lead oncology candidates Dasynoc and Nilopki to the U.S. Food and Drug Administration in the fourth quarter of 2026. The company reports that preparations are progressing as...
Xspray Pharma Highlights CML Data Differentiating Dasynoc and Nilopki
Xspray Pharma will showcase new clinical data on its chronic myeloid leukemia candidates Dasynoc and Nilopki at the ESH-iCMLf John Goldman Conference in Gothenburg, highlighting how its HyNap technology improves drug exposure predictability and reduc...
Xspray Pharma to Showcase Commercial Oncology Strategy at Gothenburg Investor Update
Xspray Pharma is organizing an Investor Update in Gothenburg on October 2, 2026, held alongside the ESH-iCMLf John Goldman Conference on Chronic Myeloid Leukemia, with participation available both on-site at Gothia Towers and online. The event will f...
Xspray Pharma to Hold Investor Update Alongside Key Leukemia Conference
Xspray Pharma is organizing an Investor Update in Gothenburg on October 2, 2026, alongside the ESH-iCMLf John Goldman Conference on Chronic Myeloid Leukemia. The event targets investors, shareholders and analysts, offering both on-site and online par...
Xspray Pharma Schedules Call After FDA Response on Lead Cancer Drug Dasynoc
Xspray Pharma has called a conference call for investors, analysts and media after receiving a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for lead drug candidate Dasynoc. Chief executive Bla...
Xspray Pharma Gets FDA Complete Response Letter on Dasynoc, Speeds Manufacturing for 2026 Resubmission
Xspray Pharma has received a Complete Response Letter from the FDA for its lead oncology candidate Dasynoc, with the agency’s concerns focused on Good Manufacturing Practice observations and the need for additional commercial-scale batch data f...
Xspray Pharma Bolsters Finances as FDA Decisions Loom for Nilopki and Dasynoc
Xspray Pharma reported another loss-making quarter in Q2 2026 with no net sales, but improved earnings before tax compared with the prior year and a strengthened balance sheet, as cash and cash equivalents rose to SEK 179.9 million. Operating cash fl...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 03, 2026